STOCK TITAN

[SCHEDULE 13G] Apogee Therapeutics, Inc. Passive Investment Disclosure (>5%)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

The Vanguard Group has disclosed a significant stake in Apogee Therapeutics Inc. As of 12/31/2025, Vanguard reports beneficial ownership of 2,857,824 shares of Apogee common stock, representing 5.21% of the class.

Vanguard reports no sole voting or dispositive power. It has shared voting power over 374,247 shares and shared dispositive power over 2,857,824 shares. The holdings are for clients, who have rights to dividends and sale proceeds, with no single client exceeding 5% of the class.

Vanguard states the shares were acquired and are held in the ordinary course of business, not to change or influence control of Apogee. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies.

Positive

  • None.

Negative

  • None.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:01/30/2026